(RTTNews) - Enanta Pharmaceuticals, Inc. (ENTA) said the final data for EDP-514 from phase 1b studies in viremic and NUC-suppressed chronic HBV patients, gives the company continued confidence in EDP-514 as a potential treatment for class II hepatitis B virus. At 800 mg, EDP-514 continued to show that it is safe and well-tolerated up to 28 days when dosed alone or in combination with NUC, in the NUC-suppressed patients. EDP-514 has strong antiviral activity across all dose groups, the company noted.
"These data are supportive of a once-daily oral dosing regimen that could provide a foundation for a combination therapy approach to achieve functional cures for chronic HBV patients," said Jay Luly, President and CEO of Enanta Pharma.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
